78 completed, 7 withdrawn, 5 unknown, 4 recruiting. 98 Phase 2, 16 Phase 3, 7 Phase 1.
Follow Conjunctivitis: new trials by email Literature Review of Conjunctivitis trials Research Report on Conjunctivitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis SUM-191, Placebo - Bacterial Conjunctivitis | Phase 1 / Phase 2 | Recruiting | Senju USA, Inc. | 426 | 2026-06-25 | 2026-06-30 |
| A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis Slit Lamp Examination, Far Best Corrected Visual Acuity (BCVA), T1695 - Moderate to Severe Vernal Keratoconjunctivitis | Phase 2 | Recruiting | Laboratoires Thea | 120 | 2026-03-24 | 2026-04-22 |
| A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease BRM421 Ophthalmic Solution, 0.03%, Artificial Tear, BRM421 Ophthalmic Solution, 0.06% - Dry Eye Disease (DED), Keratoconjunctivitis Sicca | Phase 2 | Not yet recruiting | BRIM Biotechnology Inc. | 99 | 2025-12-01 | 2025-10-20 |
| Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis TL-925, Placebo - Allergic Conjunctivitis | Phase 2 | Recruiting | Telios Pharma, Inc. | 60 | 2025-10-23 | 2025-11-25 |
| Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis TL-925, Placebo - Allergic Conjunctivitis | Phase 2 | Recruiting | Telios Pharma, Inc. | 66 | 2024-10-03 | 2024-11-13 |
| A Study Of TL-925 For The Treatment of AC TL-925, Placebo - Allergic Conjunctivitis | Phase 2 | Completed | Telios Pharma, Inc. | 80 | 2024-04-11 | 2024-07-03 |
| Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease INV-102, Vehicle - Dry Eye Disease | Phase 2 | Completed | Invirsa, Inc. | 109 | 2024-03-27 | 2026-09-18 |
| A Study of TL-925 for the Treatment of Allergic Conjunctivitis TL-925, Placebo - Allergic Conjunctivitis | Phase 2 | Unknown | Telios Pharma, Inc. | 70 | 2023-11-01 | 2023-12-01 |
| Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis INV-102, Vehicle - Acute Infectious Keratoconjunctivitis | Phase 2 | Completed | Invirsa, Inc. | 93 | 2023-06-09 | 2026-09-18 |
| Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease INV-102, Vehicle - Dry Eye Disease | Phase 1 / Phase 2 | Completed | Invirsa, Inc. | 84 | 2022-08-30 | 2026-09-18 |
| Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants REGN5713, REGN5714, REGN5715 - Allergic Rhinitis, Conjunctivitis | Phase 2 | Completed | Regeneron Pharmaceuticals | 217 | 2022-08-15 | 2024-11-19 |
| Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3 - Dry Eye Disease, Kerato Conjunctivitis Sicca | Phase 2 | Completed | Glaukos Corporation | 226 | 2022-01-03 | 2023-07-12 |
| Levocarnitine for Dry Eye in Sjogren's Syndrome Levocarnitine, Placebo - Sjogren's Syndrome, Keratoconjunctivitis Sicca | Phase 2 | Completed | Vanderbilt University Medical Center | 15 | 2021-11-17 | 2025-12-04 |
| Assessment of the Effects and Tolerability of RD03/2016 for the Treatment of Bacterial Conjunctivitis in Adults RD03/2016 eye drops, Levofloxacin 0.5% eye drops solution (Oftaquix®) - Conjunctivitis, Bacterial | Phase 2 | Completed | NTC srl | 252 | 2021-11-05 | 2024-09-27 |
| Treatment of Dry Eye Disease Using Pro-ocular™ - A Proof of Concept, Safety, and Efficacy Study Pro-ocular™ Topical Gel, Placebo Topical Gel - Dry Eye Syndrome, Keratoconjunctivitis Sicca | Phase 2 | Unknown | PharmaDax Inc. | 80 | 2021-05-20 | 2021-05-14 |
| The Efficacy Of SCH1 In The Treatment Of Acute Infectious Conjunctivitis SCH-1, Placebo - Acute Infectious Conjunctivitis (Disorder) | Phase 2 | Completed | Sacsh | 30 | 2021-03-01 | 2026-04-14 |
| Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies VSJ-110, Placebo - Allergic Conjunctivitis | Phase 2 | Completed | Vanda Pharmaceuticals | 47 | 2020-11-21 | 2025-09-11 |
| Mesenchymal Stem Cell Therapy of Dry Eye Disease in Patients With Sjögren's Syndrome ASCs, Cryostor CS10 - Keratoconjunctivitis Sicca, in Sjogren's Syndrome | Phase 2 | Completed | Copenhagen University Hospital, Rigshospitalet | 40 | 2020-11-03 | 2023-03-08 |
| A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease ECF843, ECF843 vehicle - Dry Eye | Phase 2 | Completed | Novartis Pharmaceuticals | 718 | 2020-10-06 | 2025-01-28 |
| Therapeutic Effect of Tacrosolv in Patients With Allergic Rhinoconjunctivitis Eye Drops, Solution in Single-Dose Container - Allergic Conjunctivitis, Allergic Rhinitis | Phase 2 | Completed | Marinomed Biotech AG | 64 | 2020-08-04 | 2022-08-25 |
Showing 20 of 98. Sign in to see all of them.
Conjunctivitis, Allergic (48) · Keratoconjunctivitis Sicca (26) · Dry Eye Syndromes (23) · Conjunctivitis, Bacterial (8) · Rhinitis, Allergic, Seasonal (7) · Hypersensitivity (6) · Rhinitis, Allergic (5) · Asthma (4) · Rhinitis (4) · Keratoconjunctivitis (3) · Sjogren's Syndrome (3) · Conjunctivitis, Viral (2) · Corneal Diseases (2) · Keratitis (2)
Conjunctival Diseases (98) · Eye Diseases (97) · Immune System Diseases (57) · Hypersensitivity, Immediate (51) · Hypersensitivity (47) · Corneal Diseases (29) · Keratitis (27) · Lacrimal Apparatus Diseases (27) · Keratoconjunctivitis (25) · Infections (19) · Respiratory Tract Diseases (16) · Nose Diseases (15) · Otorhinolaryngologic Diseases (15) · Eye Infections (13)
Dexamethasone (3) · Ophthalmic Solutions (3) · Cyclosporine (2) · Cyclosporins (2) · Ketotifen (2) · Loteprednol Etabonate (2) · Lubricant Eye Drops (2) · Methylprednisolone (2) · Sodium Chloride (2) · Tacrolimus (2) · besifloxacin (2) · isopropyl 5,12-hydroxypentadeca-8,10-dien-6,14-diynoate (2) · rebamipide (2) · Azithromycin (1) · BID protein, human (1)
Bausch & Lomb Incorporated (8) · Alcon Research (5) · ALK-Abelló A/S (4) · Aldeyra Therapeutics, Inc. (4) · Telios Pharma, Inc. (4) · Invirsa, Inc. (3) · Laboratorios Leti, S.L. (3) · Aciex Therapeutics, Inc. (2) · Faes Farma, S.A. (2) · Fovea Pharmaceuticals SA (2) · Kubota Vision Inc. (2) · Laboratorios Sophia S.A de C.V. (2) · National Eye Institute (NEI) (2) · NovaBay Pharmaceuticals, Inc. (2) · Rigel Pharmaceuticals (2)
United States (55) · Spain (5) · Canada (4) · Germany (4) · Austria (2) · Brazil (2) · Denmark (2) · India (2) · Israel (2) · Italy (2) · Mexico (2) · Poland (2) · Taiwan (2) · Thailand (2) · United Kingdom (2)
Gail Torkildsen, MD (4) · Gail L Torkildsen, MD (2) · Robert Shalwitz, MD (2) · Alessandra Cesano, MD (1) · Ander Sologuren, MD (1) · Anne Marie Lynge Pedersen, PhD, DDS (1) · Bruce D Gaynor, MD (1) · Carl Gustaf Laurell, MD PhD (1) · Christine Shieh, MD (1) · Christophe Baudouin, Pf. (1) · Christopher Thompson, MD (1)
PMID 24836393, PMID 25788949, PMID 26507708, PMID 18595980, PMID 19393842, PMID 19843481, PMID 20304499, PMID 20629472, PMID 20642205, PMID 21397770, PMID 21771118, PMID 22093109, PMID 22385366, PMID 22420526, PMID 22644963, PMID 22991696, PMID 23484763, PMID 23622121, PMID 23706715, PMID 26733410, PMID 28007090, PMID 29602567, PMID 30326954, PMID 30472801, PMID 32407947, PMID 32826644, PMID 32841261, PMID 33710587, PMID 34857814, PMID 35585427, PMID 35747196, PMID 36944128, PMID 37438187, PMID 37872059, PMID 38687061, PMID 39386177
2008 (2), 2005 (1), 2019 (1), 2025 (1), K23EY019881 (1), R34EY017626 (1)